| Rank |
Status |
Study |
| 1 |
Recruiting
|
Study of Anesthesia Techniques to Reduce Nausea and VOMITING After Jaw Corrective Surgery
| Conditions: |
Post-operative Nausea; Post-operative VOMITING; Post-discharge Nausea; Post-discharge VOMITING |
| Intervention: |
Other: Anesthesia and postoperative medication and fluid protocol |
| Outcome Measures: |
Post-operative nausea and VOMITING; Hospital length of stay; Post-discharge nausea and VOMITING |
|
| 2 |
Recruiting
|
Efficacy of Ondansetron on VOMITING Due to Acute Gastroenteritis in Pediatric During Winter
| Conditions: |
VOMITING; Gastroenteritis |
| Intervention: |
Drug: Ondansetron |
| Outcome Measures: |
Success will be defined by the absence of VOMITING between 15 minutes and 4 hours after administration of study treatment.; Hospital admissions for acute gastroenteritis, intravenous infusion for rehydration, return emergency department visit, severity and duration of diarrhea and VOMITING. Treatment safety will also be assessed. These criteria will be assessed within 7 days |
|
| 3 |
Recruiting
|
Prevention of Chemotherapy Induced Nausea and VOMITING in Breast Cancer Patients.
| Condition: |
Emesis |
| Interventions: |
Drug: Dexamethasone, Ondansetron, Aprepitant; Other: Arm A: Standard Anti-emetic regimen |
| Outcome Measures: |
Incidence of change in acute emesis (nausea and/or VOMITING) in both study arms; Incidence of change in the delayed emesis (nausea and/or VOMITING) in both study arms |
|
| 4 |
Recruiting
|
Effectiveness of Aprepitant in Addition to Ondansetron in the Prevention of Nausea and VOMITING Caused by Upper Abdominal Radiotherapy
| Conditions: |
Nausea; VOMITING |
| Interventions: |
Drug: aprepitant; Drug: Ondansetron |
| Outcome Measures: |
Complete Response rate (no VOMITING and no rescue anti-emetic therapy); Complete Response rate; Proportion of patients who did not vomit; No Significant Nausea: The proportion of patients who did not experience any nausea ≥ 3 on 0 - 10 scale; No Nausea: The proportion of patients who did not experience any nausea. Nausea = 0 on 0 - 10 scale; Complete Protection: The proportion of patients who did not vomit, require rescue therapy, or have nausea ≥ 3 on 0 - 10 scale; Total Protection: The proportion of patients who did not vomit, require rescue therapy, or have any nausea (Nausea = 0 on 0 - 10 scale).; VOMITING frequency: The frequency of VOMITING (# episodes per week) in patients who did vomit at least once.; Nausea frequency: The frequency of nausea (Nausea > 0 in a given week/ number of weeks during overall period of radiation treatment); Significant Nausea frequency: The frequency of significant nausea (Nausea ≥ 3 in a given week/ number of weeks during overall period of radiation treatment); Frequency of rescue medication use: The number of days in which rescue medication was taken / number of days of radiotherapy; Time to Failure: The time period in days from the start of radiation until the first VOMITING episode or use of rescue medication for all patients and for the subset of patients who do not have a Complete Response.; All adverse events that occur during radiation treatment with assessment of severity (CTC v.3) and relationship to study drug. |
|
| 5 |
Recruiting
|
A Korean Study of Efficacy and Safety of Aprepitant-based Triple Regimen for the Prevention of Chemotherapy-Induced Nausea and VOMITING in the First Cycle of Moderately Emetogenic Chemotherapy (Non-doxorubicin Hydrochloride [Adriamycin] and Cyclophosphamide Regimens) (MK-0869-225 AM1) (KMEC)
| Conditions: |
Nausea; VOMITING |
| Interventions: |
Drug: Aprepitant; Drug: Aprepitant Placebo; Drug: Ondansetron; Drug: Dexamethasone; Drug: Ondansetron Placebo; Drug: Rescue Therapy (granisetron, dolasetron, tropisetron or ondansetron; metoclopramide or alizapride). |
| Outcome Measures: |
The Proportion of Participants with Overall No VOMITING for the Overall Stage; Number of Participants with a Complete Response - Overall, Acute, and Delayed; Time to First VOMITING Event Overall; Number of Participants with No VOMITING and No Significant Nausea; Number of Participants with No Impact on Daily Life - Overall; Number of Participants with No Use of a Rescue Therapy - Overall, Acute, and Delayed; Number of Participants with One or More Clinical Adverse Events; No VOMITING - Acute and Delayed |
|
| 6 |
Recruiting
|
Evaluation of Predictive Risk Factors of Chemotherapy-induced Nausea and VOMITING
| Conditions: |
Chemotherapy-induced Nausea and VOMITING; Moderate Emetogenic Chemotherapy |
| Intervention: |
|
| Outcome Measures: |
To evaluate the role of some predictive biomarkers for chemotherapy-induced nausea and VOMITING; To evaluate the clinical characteristics related to chemotherapy-induced nausea and VOMITING in Korean patients |
|
| 7 |
Recruiting
|
Intravenous Lidocaine in the Prevention of Postoperative VOMITING in Elective Tonsil Surgery
| Conditions: |
Postoperative Nausea and VOMITING; Pain After Surgery |
| Intervention: |
Drug: Lidocaine |
| Outcome Measures: |
Evaluating the effectiveness of intravenous lidocaine during anesthesia to decrease the numbers of events (VOMITING) during the immediate postoperative period up to 24 hours postoperatively, comparing to placebo; The prevention of the composite "nausea / or VOMITING"; Compare frequency of VOMITING by baseline risk; Time to first VOMITING; Time at which discharge criteria are met Postanesthesia care unit (PACU); Length of stay in PACU unit; PACU opioid consumption; Postoperative pain using Children and Infants Postoperative Pain Scale , face or Visual analoge Scale, as appropriate; Postoperative agitation using Pediatric Anesthesia Emergence Delirium Scale; Time to first emetic drug administered; Type and number of doses of antiemetic drug requiered during hospitalization; Total length of stay; Analysis of cost-effectiveness. |
|
| 8 |
Unknown †
|
Oral Aprepitant and Lower Dose Dexamethasone Versus Aprepitant Alone for Preventing Postoperative Nausea and VOMITING (PONV) After Elective Laparoscopic Surgeries
| Conditions: |
Nausea; VOMITING |
| Interventions: |
Drug: Dexamethasone; Drug: Aprepitant; Drug: Placebo Dexamethasone |
| Outcome Measures: |
the incidences of nausea, VOMITING, need for rescue medication; incidences of unplanned hospital admission; duration of PACU stay |
|
| 9 |
Recruiting
|
Fosaprepitant Dimeglumine and Granisetron Transdermal System in Preventing Nausea and VOMITING in Patients With Breast Cancer Undergoing Chemotherapy
| Conditions: |
Breast Cancer; Nausea; VOMITING |
| Interventions: |
Drug: granisetron transdermal system; Drug: fosaprepitant dimeglumine; Other: laboratory biomarker analysis |
| Outcome Measures: |
Proportion of patients with complete response, defined as no emesis and no use of rescue medication in acute phase (within first 24 hours of treatment); Proportion of patients with complete response, defined as no emesis and no use of rescue medication in delayed phase (within 2-4 days of treatment); Proportion of patients with complete response, defined as no nausea, defined as Visual Analog Scale (VAS) less than 5 mm on a 0-100mm horizontal scale in acute phase (within 24 hours of treatment); Proportion of patients with complete response, defined as no nausea, defined as VAS less than 5 mm on a 0-100mm horizontal scale in delayed phase (within 2-4 days of treatment); Proportion of patients with partial response, defined as 2 or fewer episodes of emesis (Common Terminology Criteria for Adverse Events [CTCAE] version 4.0 grade 1-2), regardless of the use of rescue antiemetic medications (in acute and delayed phase); Proportion of patients with treatment failures, defined as more than 2 episodes of emesis (CTCAE version 4.0 grade 2 or greater), regardless of the use of rescue antiemetic medications; Proportion of patients with partial response, defined as no significant nausea, defined as VAS less than 25 mm on a 0-100mm horizontal scale (in acute and delayed phase); Proportion of patients who developed nausea and VOMITING in the first course of treatment out of all enrolled patients; Proportion of patients who developed grade 1, 2, 3, or 4 nausea and VOMITING with all courses of treatment out of all patients who developed nausea and VOMITING; Proportion of patients who developed nausea and VOMITING on all courses; Proportion of patients who experience grade 1, 2, 3, or 4 adverse events out of all patients who have received study drugs; Proportion of patients who missed 0, 1, or more than 2 doses of scheduled antiemetic medication at home on days 2 to 3, out of all patients |
|
| 10 |
Unknown †
|
B6 Treatment for Nausea and VOMITING in Pregnancy
| Condition: |
Nausea and VOMITING Complain in Early Pregnancy |
| Intervention: |
Drug: vitamin B6 |
| Outcome Measures: |
Nausea and VOMITING score; Vitamin B6 concentration in nausea and VOMITING of pregnancy |
|
| 11 |
Not yet recruiting
|
Do Pharyngeal Packs During Orthognathic Surgery Reduce Postoperative Nausea and VOMITING
| Conditions: |
Nausea; VOMITING |
| Intervention: |
Device: pharyngeal pack |
| Outcome Measures: |
the incidence and severity of any nausea, emetic episodes (retching or VOMITING), or both (i.e., postoperative nausea and VOMITING) during the first 24 postoperative hours.; The incidence and severity of throat pain; the incidence of oral mucosal injury; satisfactory scores of patients |
|
| 12 |
Not yet recruiting
|
Antiemetic Therapy With or Without Olanzapine in Preventing Chemotherapy-Induced Nausea and VOMITING in Patients With Cancer Receiving Highly Emetogenic Chemotherapy
| Conditions: |
Hematopoietic/Lymphoid Cancer; Nausea and VOMITING; Unspecified Adult Solid Tumor, Protocol Specific |
| Interventions: |
Drug: Olanzapine; Drug: Chemotherapy (cisplatin or cyclophosphamide and doxorubicin); Drug: Antiemetic treatment (ondansetron or granisetron or palonosetron; plus dexamethasone; plus fosaprepitant or aprepitant); Other: Placebo |
| Outcome Measures: |
Proportion of patients with no nausea, defined as a response of 0 in the nausea item of Nausea and VOMITING Daily Diary/Questionnaire; Nausea scores measured by the Nausea and VOMITING Daily Diary/Questionnaire; Complete response, defined as no emetic episodes and no use of rescue medication measured by the Nausea and VOMITING Daily Diary/Questionnaire; Incidence of potential toxicities related to olanzapine as measured by the Nausea and VOMITING Daily Diary/Questionnaire; Frequency of rescue medication repeatedly measured by the Nausea and VOMITING Daily Diary/Questionnaire |
|
| 13 |
Recruiting
|
Does First Oral Intake After Emergence Predict the Incidence of Post-operative VOMITING in Children?
| Condition: |
Post-operative VOMITING |
| Interventions: |
Other: Apple Juice; Other: Water |
| Outcome Measure: |
Post-operative VOMITING |
|
| 14 |
Recruiting
|
Nausea and VOMITING in Children Receiving Chemotherapeautic Monotherapy
| Condition: |
Acute Leukemia |
| Intervention: |
|
| Outcome Measures: |
Acute Chemotherapy-Induced Nausea and VOMITING; Anticipatory Chemotherapy-Induced Nausea and VOMITING; Delayed Chemotherapy-Induced Nausea and VOMITING |
|
| 15 |
Recruiting
|
Postoperative VOMITING in Children - Is Dextrose Effective for Prevention?
| Condition: |
Postoperative VOMITING |
| Interventions: |
Drug: Dextrose (D5NS); Drug: Ondansetron (Control) |
| Outcome Measures: |
Incidence of Postoperative VOMITING; Type and number of rescue antiemetic medications |
|
| 16 |
Unknown †
|
Does Thiamine Help VOMITING and Nausea in Pregnancy?
| Condition: |
Hyperemesis Gravidarum |
| Intervention: |
Drug: thiamine & promethazine |
| Outcome Measure: |
the improvement in nausea and/or VOMITING after treatment |
|
| 17 |
Recruiting
|
Transcutaneous Electrical Acupoint Stimulation (TEAS) of P6 to Prevent Postoperation Nausea and VOMITING (PONV)
| Condition: |
Postoperative Nausea and VOMITING |
| Interventions: |
Device: Transcutaneous electrical acupoint stimulation; Device: Sham transcutaneous electrical acupoint stimulation; Drug: Tropisetron; Drug: Dexamethasone |
| Outcome Measures: |
Incidence of postoperative nausea and VOMITING; Incidence of postoperative nausea; incidence of postoperative VOMITING; Number of Participants with Adverse Events |
|
| 18 |
Recruiting
|
Dexamethasone and Ondansetron Versus Placebo for Postoperative Nausea and VOMITING
| Condition: |
Postoperative Nausea and VOMITING |
| Interventions: |
Drug: Dexamethasone and Ondansetron; Drug: Placebo |
| Outcome Measures: |
Postoperative nausea or VOMITING; incidence of nausea; incidence of VOMITING; rescue treatment; pain; sedation |
|
| 19 |
Recruiting
|
Dexamethasone for the Treatment of Established Postoperative Nausea and VOMITING
| Conditions: |
Postoperative Nausea and VOMITING; VOMITING |
| Interventions: |
Drug: Injection of Placebo (saline 0.9%); Drug: Dexamethasone 3 mg intravenously; Drug: Dexamethasone 6 mg; Drug: Dexamethasone 12 mg |
| Outcome Measures: |
Treatment efficacy of Dexamethasone for established PONV; Evaluation of the potential adverse effect profile of dexamethasone |
|
| 20 |
Not yet recruiting
|
Study of Prevention of Postoperative Nausea and VOMITING Using Cesamet
| Condition: |
Postoperative Nausea and VOMITING |
| Intervention: |
Drug: Nabilone |
| Outcome Measures: |
Incidence of postoperative nausea and/or VOMITING; Number of antiemetic rescue medications given postoperatively. |
|
